Spectrometric Assessment of Generic and Brand Drug Quality for a Sentinel Screening Network

Summary: This article discusses the challenges of monitoring pharmaceutical manufacturing quality in the US and the importance of alternative strategies, such as end-product testing and screening, to monitor drug quality. The FDA, large buying groups, and the US Department of Defense are encouraged to consider these alternative strategies to enhance current regulatory activities.